1. Cancer.net . Pancreatic cancer: treatment options: ASCO (American Society of Clinical Oncology); [updated 12/2016; cited 2017 6/6]. Available from: http://www.cancer.net/cancer-types/pancreatic-cancer/treatment-options .
2. ANSM. Summary of product characteristics (Gemcitabine): Agence nationale de sécurité du médicament et des produits de santé; [updated 29/11/2013; cited 2017 16 june]. Available from: http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0233325.htm .
3. Cancer.gov . Combination of Nab-paclitaxel and gemcitabine improves survival in patients with metastatic pancreatic cancer: National Cancer Institute; [updated 15/11/13; cited 2017 07/06]. Available from: https://www.cancer.gov/types/pancreatic/research/nab-paclitaxel-gemcitabine .
4. EMA. Summary of product characteristics (Nab-paclitaxel): European Medicine Agency; [cited 2017 16 june]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000778/WC500020435.pdf .
5. Oliveras-Ferraros C, Vazquez-Martin A, Colomer R, De Llorens R, Brunet J, Menendez JA. Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling. Int J Oncol. 2008;32(1):113–20.